Glycoprotein News and Research

RSS

Study shows fused lung cells are pervasive in severe COVID-19

In a recent bioRxiv paper, scientists from Institut Pasteur and other research centers in France demonstrated how pathological effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are modulated by cellular proteins that can either inhibit or facilitate cell fusion and subsequent syncytia formation.

16 Jul 2020

Common FDA-approved drug may be a powerful tool in fighting COVID-19

A common drug, already approved by the Food and Drug Administration, may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.

15 Jul 2020

Mobility and flexibility in SARS-CoV-2 proteins

Now, a new study published on the preprint server bioRxiv in July 2020 describes the use of in silico modeling of potential drug targets on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein structures, using data retrieved from the Protein Databank (PDB).

15 Jul 2020

Absolute Antibody and University of Zurich partner to offer novel SARS-CoV-2 sybodies

Absolute Antibody Ltd., an industry-leading provider of recombinant antibody products and services, today announced a partnership with University of Zurich to offer synthetic nanobodies against the receptor binding domain (RBD) of SARS-CoV-2, the coronavirus that causes COVID-19.

From Absolute Antibody Ltd 14 Jul 2020

A new measles-based COVID-19 vaccine

Now, a new study by researchers from Germany's Paul Ehrlich Institute and published on the preprint server bioRxiv in July 2020 describes a potential vaccine based on the measles vaccine, which elicits both an antibody response and cellular immunity against the virus. This also protects against the measles virus. This could be a significant weapon in the fight against these two threats.

14 Jul 2020

Researchers stabilize the closed SARS-CoV-2 spike trimer

Now, a new study by researchers at Janssen Vaccines & Prevention BV and Leiden University and published on the preprint server bioRxiv uses cryoEM to reveal the structure of this trimer, in order to support both vaccine development and diagnostic testing based on antibody production.

14 Jul 2020

Study identifies three novel broad-spectrum SARS-CoV-2 cell entry inhibitors

Researchers from the National Institutes of Health (NIH) and Cornell University in the U.S. just described several new inhibitors of human coronavirus spike proteins by screening a library of approved drugs with SARS-S and MERS-S pseudotyped particle entry assays. Their exciting findings are currently available on the bioRxiv preprint server.

13 Jul 2020

As winter comes other viruses will compete with SARS-CoV-2 for susceptible hosts

A new study published on the preprint server medRxiv in July 2020 traces how COVID-19 became the predominant cause of respiratory infection in the period from early January until the present.

10 Jul 2020

Study of glycosylation on SARS-CoV-2 spike protein

The first intimation of the current COVID-19 crisis came with the news of severe pneumonic illness caused by an unknown agent in a Chinese city called Wuhan, issued on the last day of 2019. Following this, researchers found the cause to be a novel coronavirus, closely related to the earlier SARS virus, now called severe acute respiratory syndrome coronavirus 2.

8 Jul 2020

Gene expression networks flag potential therapeutic targets for SARS-CoV-2

An international team of researchers from Canada, Australia, the Netherlands, and the United States has identified dozens of genes that could contribute to the pathology of coronavirus disease 2019 (COVID-19) and serve as potential therapeutic targets.

7 Jul 2020

Oxford COVID-19 vaccine trials move to stage 3 human trials

The technical name of the vaccine is ChAdOx1 nCoV-19 (AZD1222), as it is made from a virus called ChAdOx1, which is a weakened and non-replicating version of a common cold virus (adenovirus). The vaccine has been engineered to express the SARS-CoV-2 spike protein.

5 Jul 2020

Study: Variation in COVID-19 viral genome improves its ability to infect human cells

Researchers have shown that a variation in the viral genome of Covid-19 improved its ability to infect human cells and helped it become the dominant strain circulating around the world today.

3 Jul 2020

Mutated European strain of coronavirus more contagious but less potent

The coronavirus pandemic is far from over as it actively spreads across the globe. The infection toll has reached a staggering 10.84 million people since it emerged in late December 2019 in Wuhan City, China. The virus that has left the city has now spread to 188 countries and territories and has mutated, becoming more infectious.

3 Jul 2020

Novavax SARS-CoV-2 vaccine candidate shows promise in animal models

A new study published on the preprint server bioRxiv in June 2020 shows that a candidate spike protein vaccine can induce neutralizing antibodies, antiviral T cell responses, and protection against infection.

2 Jul 2020

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

Striking CryoEM image of SARS-CoV-2

A new study by researchers from the UK and Germany and published on the preprint server bioRxiv in June 2020 reports the results of a detailed study of the S protein on the intact virus, using cryoelectron microscopy (cryoEM) and tomography. This could help understand the conformation of the S protein on the virion and how it interacts with neutralizing antibodies.

30 Jun 2020

A glycan analysis of SARS-CoV-2 ACE2 complex

Researchers in the U.S. have produced molecular dynamic simulations of the Spike protein found on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its interaction with the host cell receptor angiotensin-converting enzyme 2 (ACE2).

29 Jun 2020

COVID-19 patients can rapidly generate virus-attacking T cells, shows study

Patients suffering from severe respiratory symptoms as a result of SARS-CoV-2 infection can rapidly generate virus-attacking T cells, and can increase this production over time, suggests a new study of T cells from 10 COVID-19 patients under intensive care treatment.

27 Jun 2020

Genes associated with SARS-CoV-2 human lung cell infection

Now, a new study published on the preprint server bioRxiv in June 2020 attempts to make sense of this data to identify viral genes that are explicitly expressed in the cells infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This could help reveal new therapeutic targets.

26 Jun 2020

Early childhood vaccinations may offer protection against COVID-19

A group of Lithuanian and Kurdish scientists have raised a hypothesis that the measles, mumps, and rubella (MMR) vaccine could protect children from COVID-19.

25 Jun 2020